

MAILED 10

3.1 JAN 2006

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 444 RLI-301US	
In Re Application Of: BABU et al. 10/532910						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/532,910		Unknown	26815	Unknown	2279	
Title: PROCESS FOR THE PREPARATION OF GANCICLOVIR						
<div style="text-align: center;"> <p>Address to:</p> <p>Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> </div> <div style="text-align: center; margin-top: 10px;"> <p>37 CFR 1.97(b)</p> </div> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <div style="text-align: center; margin-top: 20px;"> <p>37 CFR 1.97(c)</p> </div> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px; margin-top: 10px;"> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin-top: 10px;">OR</p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> </div>						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

RLL-301US

In Re Application: **BABU et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/532,910		Unknown	26815	Unknown	2279

Title: **PROCESS FOR THE PREPARATION OF GANCICLOVIR****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by ^{EXPRESS} First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as ^{EXPRESS} first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.97(c)] on

January 31, 2006

(Date)

Signature of Person Mailing Correspondence

Michelle Morgan

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: January 31, 2006

George E. Heibel, Esq.

Reg. No. 42,648

CUSTOMER NO. 26815

CC:

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-301US

Serial No.: 10/532,910

Applicants: BU et al.

Filed: 4/27/2005

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,146,715	3/27/1979	Schaeffer	544	276	
	A2	4,355,032	10/19/1982	Verheyden et al.	424	253	
	A3	5,792,868	8/11/1998	Izawa et al.	544	276	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	EP 0 074 306	3/16/1983	EPO	C07D	473/18		
	B2	EP 0 138 683	4/24/1985	EPO	C07D	473/16		
	B3	EP 0 165 164	12/18/1985	EPO	C07D	473/18		
	B4	EP 0 532 878	6/30/1999	EPO	C07D	473/00		
	B5	JP 59-80685	5/10/1984	Japan	C07D	473/18		
	B6	WO 03/033498	4/24/2003	PCT	C07D	473/18		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Barrio et al., "A Direct Method for the Preparation of 2-Hydroxyethoxymethyl Derivatives of Guanine, Adenine, and Cytosine", <i>Journal of Medicinal Chemistry</i> , 23:572-574 (1980)
C2	Boryski et al., "Application of the Transpurination Reaction to Synthesis of Acyclic Guanosine Analogs", <i>Nucleosides & Nucleotides</i> , 8(4):529-536 (1989)
C3	Martin et al., "9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: A New Potent and Selective Antih herpes Agent", <i>Journal of Medicinal Chemistry</i> , 26:759-761 (1983)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.